Hypothyroidism and goiter in a patient during treatment with interleukin-2.
The development of transient hypothyroidism and goiter in a patient with a metastasized malignant melanoma during treatment with recombinant interleukin-2 (rIL-2) and dacarbazine is reported. Signs of autoimmune thyroiditis became apparent 2 weeks after the start of treatment and disappeared after treatment stopped. It is likely that rIL-2 was responsible by interfering with preexisting autoimmune thyroid disease. The possible mechanisms are discussed here. Patients with positive antithyroid microsomal antibody titers are prime candidates for rIL-2-induced thyroiditis.
Mattijssen
V J
VJ
Department of Medicine, University Hospital, Nijmegen, The Netherlands.
De Mulder
P H
PH
Van Liessum
P A
PA
Corstens
F H
FH
Franks
C R
CR
Wagener
D J
DJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006042:Goiter / Q000139:chemically induced*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D011994:Recombinant Proteins; D013967:Thyroiditis, Autoimmune / Q000139:chemically induced
D007376:Interleukin-2; D011994:Recombinant Proteins; D003606:Dacarbazine